BRISTOL-MYERS SQUIBB COMPANY (BMY) Current Ratio
- Current ratio · latest quarter: Value 1.53×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.53× | Current assets / current liabilities. $28.58B ÷ $18.66B ≈ 1.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 28.58B USD | Assets, Current |
| Current obligations | 18.66B USD | Liabilities, Current |
| Cash and equivalents | 8.72B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 2.35B USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 9.08B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 2.74B USD | Inventory, Net |
| Payables | 4.16B USD | Accounts Payable, Current |
| Borrowing debt due within one year | 768.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.58B | $18.66B | $8.72B | $2.35B | $9.08B | $2.74B | $4.16B | $768.00M | 1.53× |
| 2026-03-31 | $27.21B | $19.16B | $9.57B | $912.00M | $7.95B | $2.76B | $4.23B | $1.99B | 1.42× |
| 2025-12-31 | $29.39B | $23.42B | $10.21B | $464.00M | $9.59B | $2.69B | $3.58B | $1.98B | 1.26× |
| 2025-09-30 | $35.63B | $28.14B | $15.73B | $776.00M | $9.62B | $2.76B | $4.29B | $4.25B | 1.27× |
| 2025-06-30 | $33.22B | $27.53B | $12.60B | $1.00B | $9.71B | $2.74B | $5.43B | $4.47B | 1.21× |
| 2025-03-31 | $30.78B | $24.07B | $10.88B | $907.00M | $9.06B | $2.67B | $4.00B | $3.35B | 1.28× |
| 2024-12-31 | $29.78B | $23.77B | $10.35B | $513.00M | $9.01B | $2.56B | $3.60B | $1.83B | 1.25× |
| 2024-09-30 | $28.07B | $22.64B | $7.89B | $204.00M | $9.32B | $3.33B | $3.47B | $873.00M | 1.24× |
| 2024-06-30 | $26.89B | $23.27B | $6.29B | $360.00M | $9.75B | $3.08B | $3.75B | $3.09B | 1.16× |
| 2024-03-31 | $28.67B | $25.82B | $9.33B | $340.00M | $8.83B | $2.98B | $3.54B | $2.87B | 1.11× |
| 2023-12-31 | $31.77B | $22.26B | $11.46B | $816.00M | $8.88B | $2.66B | $3.26B | $2.87B | 1.43× |
| 2023-09-30 | $27.63B | $23.46B | $7.51B | $171.00M | $8.41B | $2.44B | $2.81B | $4.87B | 1.18× |
| 2023-06-30 | $28.07B | $20.15B | $8.37B | $358.00M | $8.13B | $2.36B | $3.07B | $2.41B | 1.39× |
| 2023-03-31 | $27.09B | $19.09B | $8.99B | $274.00M | $7.85B | $2.60B | $3.19B | $2.25B | 1.42× |
| 2022-12-31 | $27.27B | $21.89B | $9.12B | $130.00M | $8.15B | $2.34B | $3.04B | $3.90B | 1.25× |
| 2022-09-30 | $26.80B | $18.93B | $7.73B | $1.29B | $8.02B | $2.07B | $2.60B | $1.90B | 1.42× |
| 2022-06-30 | $30.19B | $20.91B | $10.75B | $2.48B | $7.59B | $2.14B | $2.88B | $4.65B | 1.44× |
| 2022-03-31 | $30.12B | $22.82B | $12.37B | $2.60B | $7.16B | $2.10B | $2.94B | $7.30B | 1.32× |
| 2021-12-31 | $33.26B | $21.87B | $13.98B | $2.99B | $7.98B | $2.10B | $2.95B | $4.76B | 1.52× |
| 2021-09-30 | $31.44B | $21.46B | $13.54B | $2.12B | $7.88B | $2.16B | $2.69B | $4.77B | 1.47× |
| 2021-06-30 | $29.16B | $18.99B | $11.02B | $1.95B | $7.71B | $2.14B | $3.61B | $2.50B | 1.54× |
| 2021-03-31 | $27.11B | $17.33B | $10.98B | $1.95B | $7.19B | $1.95B | $2.97B | $1.50B | 1.56× |
| 2020-12-31 | $30.19B | $19.08B | $14.55B | $1.28B | $7.22B | $2.07B | $2.71B | $2.00B | 1.58× |
| 2020-09-30 | $34.28B | $20.46B | $19.43B | $1.72B | $6.78B | $1.95B | $2.44B | $3.25B | 1.67× |
| 2020-06-30 | $34.34B | $23.42B | $19.93B | $1.72B | $6.70B | $2.38B | $2.85B | $4.25B | 1.47× |
| 2020-03-31 | $31.85B | $19.23B | $15.82B | $2.50B | $7.20B | $2.84B | $3.07B | $3.26B | 1.66× |
| 2019-12-31 | $29.35B | $18.30B | $12.35B | $3.05B | $6.48B | $4.29B | $2.44B | $2.76B | 1.60× |
| 2019-09-30 | $40.19B | $10.49B | $30.49B | $2.05B | $4.29B | $1.19B | $1.89B | $0.00 | 3.83× |
| 2019-06-30 | $37.72B | $9.71B | $28.40B | $953.00M | $4.50B | $1.31B | $2.00B | $0.00 | 3.88× |
| 2019-03-31 | $17.09B | $8.84B | $7.33B | $1.43B | $4.59B | $1.28B | $1.98B | $0.00 | 1.93× |
| 2018-12-31 | $17.72B | $10.65B | $6.91B | $1.85B | $4.64B | $1.20B | $1.89B | $1.25B | 1.66× |
| 2018-09-30 | $14.87B | $9.69B | $5.41B | $1.42B | $4.62B | $1.28B | $1.77B | $1.25B | 1.53× |
| 2018-06-30 | $13.87B | $9.88B | $5.00B | $1.08B | $4.32B | $1.24B | $1.87B | $1.26B | 1.40× |
| 2018-03-31 | $14.65B | $9.62B | $5.34B | $1.43B | $4.37B | $1.23B | $1.73B | $1.25B | 1.52× |
| 2017-12-31 | $14.85B | $9.56B | $5.42B | $1.39B | $4.35B | $1.17B | $2.25B | $0.00 | 1.55× |
| 2017-09-30 | $15.05B | $9.44B | $4.64B | $2.48B | $4.33B | $1.25B | $1.70B | (m) | 1.59× |
| 2017-06-30 | $14.32B | $9.02B | $3.47B | $3.04B | $4.22B | $1.22B | $1.55B | $750.00M | 1.59× |
| 2017-03-31 | $13.62B | $8.49B | $3.91B | $2.20B | $4.08B | $1.38B | $1.50B | $749.00M | 1.60× |
| 2016-12-31 | $13.70B | $8.84B | $4.24B | $2.11B | $3.77B | $1.24B | $1.66B | $749.00M | 1.55× |
| 2016-09-30 | $13.20B | $9.00B | $3.43B | $2.13B | $3.81B | $1.48B | $1.41B | $749.00M | 1.47× |
| 2016-06-30 | $12.30B | $7.88B | $2.93B | $1.72B | $3.69B | $1.44B | $1.50B | (m) | 1.56× |
| 2016-03-31 | $11.21B | $7.60B | $2.64B | $1.66B | $3.36B | $1.34B | $1.54B | (m) | 1.48× |
| 2015-12-31 | $10.41B | $8.02B | $2.38B | $1.89B | $2.95B | $1.22B | $1.56B | (m) | 1.30× |
| 2015-09-30 | $12.93B | $7.16B | $3.98B | $1.44B | $2.71B | $1.13B | $1.25B | (m) | 1.81× |
| 2015-06-30 | $13.06B | $7.43B | $4.20B | $1.28B | $2.54B | $1.30B | $1.84B | (m) | 1.76× |
| 2015-03-31 | $14.93B | $7.69B | $6.29B | $1.31B | $2.25B | $1.44B | $2.35B | (m) | 1.94× |
| 2014-12-31 | $14.61B | $8.46B | $5.57B | $1.86B | $2.10B | $1.56B | $2.49B | (m) | 1.73× |
| 2014-09-30 | $14.18B | $8.10B | $4.85B | $2.37B | $1.82B | $1.56B | $2.57B | (m) | 1.75× |
| 2014-06-30 | $14.06B | $7.80B | $4.28B | $2.89B | $1.80B | $1.67B | $2.40B | (m) | 1.80× |
| 2014-03-31 | $14.01B | $7.52B | $5.22B | $1.83B | $1.74B | $1.66B | $2.50B | (m) | 1.86× |
| 2013-12-31 | $18.92B | $12.44B | $3.59B | $939.00M | $1.69B | $1.50B | $2.56B | (m) | 1.52× |
| 2013-09-30 | $10.63B | $8.28B | $1.77B | $951.00M | $1.84B | $1.64B | $2.47B | $30.00M | 1.28× |
| 2013-06-30 | $10.49B | $8.35B | $1.82B | $978.00M | $1.85B | $1.78B | $2.35B | $680.00M | 1.26× |
| 2013-03-31 | $10.08B | $8.41B | $1.35B | $1.18B | $1.80B | $1.79B | $2.08B | $658.00M | 1.20× |
| 2012-12-31 | $9.52B | $8.28B | $1.66B | $1.17B | $1.71B | $1.66B | $2.20B | (m) | 1.15× |
| 2012-09-30 | $9.28B | $8.20B | $1.50B | $1.43B | $1.73B | $1.70B | $2.08B | $619.00M | 1.13× |
| 2012-06-30 | $11.01B | $6.99B | $2.80B | $2.24B | $1.62B | $1.52B | $2.13B | (m) | 1.58× |
| 2012-03-31 | $11.77B | $7.21B | $2.31B | $2.72B | $2.25B | $1.46B | $2.38B | (m) | 1.63× |
| 2011-12-31 | $15.32B | $7.78B | $5.78B | $2.96B | $2.25B | $1.38B | $2.60B | (m) | 1.97× |
| 2011-09-30 | $14.87B | $7.31B | $4.47B | $3.72B | $2.18B | $1.36B | $2.29B | (m) | 2.03× |
| 2011-06-30 | $14.78B | $7.41B | $3.67B | $4.00B | $2.12B | $1.49B | $2.40B | (m) | 1.99× |
| 2011-03-31 | $13.30B | $6.75B | $3.40B | $3.39B | $2.05B | $1.32B | $2.04B | (m) | 1.97× |
| 2010-12-31 | $13.27B | $6.74B | $5.03B | $2.27B | $1.99B | $1.20B | $1.98B | (m) | 1.97× |
| 2010-09-30 | $14.38B | $6.28B | $7.58B | $778.00M | $1.97B | $1.37B | $1.73B | (m) | 2.29× |
| 2010-06-30 | $12.98B | $5.91B | $5.92B | $1.54B | $1.80B | $1.26B | $1.68B | (m) | 2.20× |
| 2010-03-31 | $12.53B | $6.02B | $5.13B | $1.64B | (m) | $1.28B | $1.75B | (m) | 2.08× |
| 2009-12-31 | $13.96B | $6.31B | $7.68B | $831.00M | $1.90B | $1.41B | $1.71B | (m) | 2.21× |
| 2009-09-30 | $13.39B | $7.39B | $6.37B | $302.00M | (m) | $1.82B | $1.80B | (m) | 1.81× |
| 2009-06-30 | $14.57B | $6.74B | $7.51B | $613.00M | (m) | $1.78B | (m) | (m) | 2.16× |
| 2008-12-31 | $14.70B | $6.71B | $7.98B | $289.00M | (m) | $1.76B | $1.53B | (m) | 2.19× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |